Last quarter (Q3 2023), Aptevo Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Aptevo Therapeutics's net income was $-6.33M. See Aptevo Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	$ 3.11M	$ 12.29M	$ 4.31M	$ 0.00	$ 23.07M
Cost of Revenue	-	-	-	-	$ 19.93M	$ 11.21M
Gross Profit	-	$ 3.11M	$ 12.29M	-	$ 12.50M	$ 11.85M
Operating Expense	$ 30.18M	$ 31.75M	$ 33.69M	$ 31.80M	$ 40.96M	$ 63.52M
Operating Income	$ -30.18M	$ -28.64M	$ -21.40M	$ -27.49M	$ -40.96M	$ -51.66M
Net Non Operating Interest Income Expense	-	-	-	-	-	-
Other Income Expense	$ -10.06M	$ -35.66M	$ 8.01M	$ -3.43M	$ -2.10M	$ -2.02M
Pretax Income	$ -17.62M	$ 7.01M	$ -29.41M	$ -30.92M	$ -43.06M	$ -53.69M
Tax Provision	-	-	-	-	-	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -16.15M	$ 8.03M	$ -28.46M	$ -17.75M	$ -40.45M	$ -53.69M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 30.18M	$ 31.75M	$ 33.69M	$ 31.80M	$ 40.96M	$ 74.73M
Net Income From Continuing And Discontinued Operation	$ -16.15M	$ 8.03M	$ -28.46M	$ -17.75M	$ -40.45M	$ -53.69M
Normalized Income	$ -11.28M	-	-	$ -28.82M	$ -43.06M	$ -53.69M
Interest Expense	-	-	-	-	-	-
EBIT	$ -17.62M	$ 7.01M	$ -29.41M	$ -27.49M	$ -40.96M	$ -51.66M
EBITDA	$ -17.01M	$ 7.92M	$ -28.26M	$ -26.09M	$ -38.73M	$ -49.27M

Currency in USD

Aptevo Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing